* Cabaletta Bio Inc CABA.OQ reported a quarterly adjusted
loss
of 62 cents per share for the quarter , lower than the same
quarter last year, when the company reported EPS of -37 cents.
The mean expectation of eleven analysts for the quarter was
for a loss of 60 cents per share. Wall Street expected
results to range from -64 cents to -54 cents per share.
* Reported revenue was zero; analysts expected zero.
* Cabaletta Bio Inc's reported EPS for the quarter was a
loss
of 62 cents.
* The company reported a quarterly loss of $30.63 million.
* Cabaletta Bio Inc shares had fallen by 15.0% this
quarter and
lost 82.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 0.1%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Cabaletta Bio Inc
is 24.00
This summary was machine generated from LSEG data November 14 at
02:15 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.60 -0.62 Missed
Jun. 30 2024 -0.55 -0.56 Missed
Mar. 31 2024 -0.48 -0.51 Missed
Dec. 31 2023 -0.39 -0.46 Missed